Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 4/2016

01-07-2016 | Original Article

Immunocytochemical results for HER2 and Ki67 in breast cancer touch-smear cell specimens are reliable

Authors: Masami Morimoto, Yoshimi Bando, Misako Nakagawa, Hirokazu Takechi, Takahiro Yoshida, Junko Honda, Yukiko Tadokoro, Takuya Moriya, Mitsunori Sasa, Akira Tangoku

Published in: Breast Cancer | Issue 4/2016

Login to get access

Abstract

Background

Re-evaluation of the subtype of recurrent breast cancer is necessary for deciding the treatment approach, but it is often not performed due to the difficulty of obtaining tissue specimens from a recurrent lesion, etc. However, when a recurrent lesion is close to the body surface, fine-needle aspiration cells (FNA cells) can be easily obtained, and immunocytochemical (ICC) analysis of hormone receptors expression in FNA cells is said to be highly reliable. However, there is no consensus regarding ICC analysis of human epidermal growth factor receptor type 2 (HER2) expression and the Ki67 index using FNA cells.

Methods

Touch-smear cells (TSC) were prepared from resected specimens from 36 patients with primary invasive ductal carcinoma of the breast. The TSC were fixed in 95 % ethanol and subjected to ICC analysis for HER2 using HercepTest™ (Dako) and Ki67 using MIB-1™ (Dako). HER2 expression and the Ki67 index for the TSC were compared with the results of immunohistochemical analysis of histological section (HS). Statistical analyses used the kappa test and Pearson’s correlation coefficients.

Results

HER2 and Ki67 were analyzed in TSC from 36 and 28 patients, respectively. The HER2 expression scores in the TSC and HS groups showed good agreement (kappa value =0.640) and significant correlation (correlation coefficient =0.860, p < 0.001). The Ki67 indexes in the TSC and HS groups also showed significant correlation (correlation coefficient =0.861, p < 0.001).

Conclusions

The reliability of ICC analysis of HER2 expression and the Ki67 index using TSC were recognized.
Literature
1.
Nishimura R, Aogi K, Yamamoto T, Takabatake D, Takashima S, Teramoto N, Kagawa A, Morita S. Usefulness of liquid-based cytology in hormone receptor analysis of breast cancer specimens. Virchows Arch. 2011;458:153–8.CrossRefPubMed
2.
Ferguson J, Chamberlain P, Cramer HM, Wu HHER. PR, and Her2 immunocytochemistry on cell-transferred cytologic smears of primary and metastatic breast carcinomas: a comparison study with formalin-fixed cell blocks and surgical biopsies. Diagn Cytopathol. 2013;41:575–81.CrossRefPubMed
3.
Ramljak V, Sučić M, Vrdoljak DV, Borojević N. Expression of Ki-67 and p27 (Kip1) in fine-needle aspirates from breast carcinoma and benign breast diseases. Diagn Cytopathol. 2011;39:333–40.CrossRefPubMed
4.
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. American Society of Clinical Oncology; College of American Pathologists Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.CrossRefPubMed
5.
Khasraw M, Brogi E, Seidman AD. The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? Curr Oncol Rep. 2007;13:17–25.CrossRef
6.
Bédard YC, Pollett AF, Leung SW, O’Malley FP. Assessment of thin-layer breast aspirates for immunocytochemical evaluation of HER2 status. Acta Cytol. 2003;47:979–84.CrossRefPubMed
7.
Beatty BG, Bryant R, Wang W, Ashikaga T, Gibson PC, Leiman G, et al. HER-2/neu detection in fine-needle aspirates of breast cancer fluorescence in situ hybridization and immunocytochemical analysis. Am J Clin Pathol. 2004;122:246–55.CrossRefPubMed
8.
Moriki T, Takahashi T, Ueta S, Mitani M. Ichien M. Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: correlation with histologic sections determinations and diagnostic pitfalls. Diagn Cytopathol. 2004;30:251–6.CrossRefPubMed
9.
Sumiyoshi K, Shibayama Y, Akashi S, Nohara T, Iwamoto M, Kobayashi T, et al. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections? Oncol Rep. 2006;15:803–8.PubMed
10.
Hanley KZ, Birdsong GG, Cohen C, Siddiqui MT. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations. Cancer. 2009;117:279–88.PubMed
11.
Williams SL, Birdsong GG, Cohen C, Siddiqui MT. Immunohistochemical detection of estrogen and progesterone receptor and HER2 expression in breast carcinomas: comparison of cell block and tissue block preparations. Int J Clin Exp Pathol. 2009;2:476–80.PubMedPubMedCentral
12.
Kumar SK, Gupta N, Rajwanshi A, Joshi K, Singh G. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma. Cytopathology. 2012;23:181–6.CrossRefPubMed
13.
Pegolo E, Machin P, Riosa F, Bassini A, Deroma L, Loreto CD. Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma: correlation with histologic sections determination. Cancer Cytopathol. 2012;120:196–205.CrossRefPubMed
14.
Corkill ME, Katz R. Immunocytochemical staining of c-erb B-2 oncogene in fine-needle aspirates of breast carcinoma: a comparison with tissue sections and other breast cancer prognostic factors. Diagn Cytopathol. 1994;11:250–4.CrossRefPubMed
15.
Troncone G, Panico L, Vetrani A, de Divitiis B, Zeppa P, Fulciniti F, et al. c-erbB-2 expression in FNAB smears and matched surgical specimens of breast cancer. Diagn Cytopathol. 1996;14:135–9.CrossRefPubMed
16.
Solomides CC, Zimmerman R, Bibbo M. Semiquantitative assessment of c-erbB-2 (HER-2) status in cytology specimens and tissue sections from breast carcinoma. Anal Quant Cytol Histol. 1999;21:121–5.PubMed
17.
DiGiovanna MP, Chu P, Davison TL, Howe CL, Carter D, Claus EB, Stern DF. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. Cancer Res. 2002;62:6667–73.PubMed
18.
Rita N, Cecilia B, Nadia N, Annamaria G, Marzio G, Maria M, et al. Comparison of the results of immunocytochemical assays for biologic variables on preoperative fine-needle aspirates and on surgical specimens of primary breast carcinomas. Cancer. 2000;90:61–6.CrossRef
Metadata
Title
Immunocytochemical results for HER2 and Ki67 in breast cancer touch-smear cell specimens are reliable
Authors
Masami Morimoto
Yoshimi Bando
Misako Nakagawa
Hirokazu Takechi
Takahiro Yoshida
Junko Honda
Yukiko Tadokoro
Takuya Moriya
Mitsunori Sasa
Akira Tangoku
Publication date
01-07-2016
Publisher
Springer Japan
Published in
Breast Cancer / Issue 4/2016
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-015-0605-z

Other articles of this Issue 4/2016

Breast Cancer 4/2016 Go to the issue

Original Article

Diagnostic performance of 18F-fluorodeoxyglucose PET/CT and bone scintigraphy in breast cancer patients with suspected bone metastasis

Original Article

Willingness of Japanese patients with breast cancer to have genetic testing of BRCA without burden of expenses

Original Article

Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience

Original Article

Which patients require or can skip biopsy for breast clustered microcysts? Predictive findings of breast cancer and mucocele-like tumor

Special Feature

Histological assessment of therapeutic response in breast cancer

Original Article

Analysis of prior mammography with negative result in women with interval breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits